Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Completed 5

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5Thoracic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Renal Cell 13Prostatic Neoplasms 8Urinary Bladder Neoplasms 6Kidney Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Pancreatic Neoplasms 4Neoplasm Metastasis 3Colonic Neoplasms 3Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Salivary Gland Neoplasms 2Rectal Neoplasms 2Neoplasms 2Lung Neoplasms 2Hereditary leiomyomatosis and renal cell cancer 2Glioma 2Esthesioneuroblastoma, Olfactory 2Ependymoma 2Wilms Tumor 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thrombocytosis 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Papillary renal cell carcinoma, sporadic 1Osteosarcoma 1Oligodendroglioma 1

Interventions

aldesleukin 43Sunitinib 42Cyclophosphamide 30Nivolumab 29pembrolizumab 27Everolimus 27Interferon-alpha 25Bevacizumab 23Sorafenib 22Interleukin-2 20fludarabine phosphate 19Radiotherapy 18Ipilimumab 18Filgrastim 18Axitinib 18Gene Expression Profiling 16Peripheral Blood Stem Cell Transplantation 15Gemcitabine 15cabozantinib 14Radiosurgery 13fludarabine 11Doxorubicin 11Carboplatin 11Blood Specimen Collection 11temsirolimus 10atezolizumab 9Immunohistochemistry 9Etoposide 9Chemotherapy, Adjuvant 9sargramostim 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Kidney Neoplasms × Erlotinib Hydrochloride × Genitourinary × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT01130519 2025-02-21

A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
83 enrolled 17 charts
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, Kidney Neoplasms

NCT00425386 2017-05-03

Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer

OHSU Knight Cancer Institute

Phase 2 Completed
60 enrolled 10 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00193154 2014-04-01

OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma

SCRI Development Innovations, LLC

Phase 2 Completed
63 enrolled
Genitourinary

Kidney Neoplasms

NCT00045487 2014-01-27

OSI-774

The University of Texas Health Science Center at San Antonio

Phase 2 Completed
41 enrolled 7 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡